<DOC>
	<DOCNO>NCT00000691</DOCNO>
	<brief_summary>To examine usefulness safety antiviral drug foscarnet treat AIDS patient cytomegalovirus ( CMV ) infection cause sight-threatening inflammation retina one eye ( CMV retinitis ) . Because seriousness sight-threatening CMV retinitis AIDS patient lack available treatment patient treat ganciclovir ( DHPG ) ( toxic effect body 's blood-forming cell , control disease , patient 's blood cell platelet count low begin ) , worthwhile try immediate trial foscarnet . AMENDED : ACTG 093 originally design randomize dose-ranging study foscarnet maintenance therapy . Patients enrol March 17 , 1989 , January 1 , 1990 , receive either 60 mg/kg/day 90/mg/kg day maintenance therapy follow 2 week induction period . Based preliminary result ACTG 015/915 , study maintenance dos foscarnet 60 mg/kg/day , 90 mg/kg/day 120 mg/kg/day , 60-mg/kg/day 90/mg/kg/day arm study close . All patient enter study begin January 2 , 1990 receive foscarnet maintenance therapy 120/mg/kg/day algorithm follow induction .</brief_summary>
	<brief_title>A Phase II Dose-Ranging , Open-Labelled Trial Foscarnet Salvage Therapy AIDS Patients With Sight-Threatening CMV Retinitis Who Can Be Treated With Ganciclovir Due To Myelosuppression Treatment Failure</brief_title>
	<detailed_description>Because seriousness sight-threatening CMV retinitis AIDS patient lack available treatment patient treat ganciclovir ( DHPG ) ( toxic effect body 's blood-forming cell , control disease , patient 's blood cell platelet count low begin ) , worthwhile try immediate trial foscarnet . AMENDED : ACTG 093 originally design randomize dose-ranging study foscarnet maintenance therapy . Patients enrol March 17 , 1989 , January 1 , 1990 , receive either 60 mg/kg/day 90/mg/kg day maintenance therapy follow 2 week induction period . Based preliminary result ACTG 015/915 , study maintenance dos foscarnet 60 mg/kg/day , 90 mg/kg/day 120 mg/kg/day , 60-mg/kg/day 90/mg/kg/day arm study close . All patient enter study begin January 2 , 1990 receive foscarnet maintenance therapy 120/mg/kg/day algorithm follow induction . AMENDED : The ACTG 093 optional extend maintenance therapy period conclude January 2 , 1991 order facilitate timely analysis study . All patient wish continue foscarnet therapy refer Astra Protocol 90-FOS-14 telephone number 800-292-5775 . Original design : Patients place two group : ( 1 ) patient sight-threatening lesion retina eye vision save ( correct vision 20/100 better ) treat DHPG , ( 2 ) patient whose retinitis quickly get bad and/or show resistance DHPG treatment . Both group receive begin ( induction ) dose foscarnet vein ( IV ) 2 week , follow maintenance dose 8 week option continue 24 week . AMENDED : Patients enter study 01/02/90 receive standard two week course foscarnet induction therapy receive maintenance therapy . Treatment give ten week study period progression occur toxicity endpoint reach . If retinitis stable foscarnet well-tolerated , maintenance therapy may extend period exceed 1 year .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine Pneumocystis carinii pneumonia ( PCP ) prophylaxis . Oral antibiotic patient hematologically stable regimen least 30 day prior study entry . Therapy vancomycin . Drug therapy Kaposi 's sarcoma patient hematologically stable least 30 day prior study entry . Initiate resume zidovudine ( AZT ) 2nd week foscarnet maintenance therapy dose 100 200 mg q4h investigator 's discretion . Initiate continue erythropoietin therapy via treatment IND mechanism . Initiate continue therapy investigational triazoles disseminate fungal infection . Caution use concurrent use foscarnet ciprofloxacin , use appear exacerbate renal failure one patient . Prior Medication : Allowed : Oral antibiotic patient hematologically stable regimen least 30 day prior study entry . Drug therapy Kaposi 's sarcoma patient hematologically stable least 30 day prior study entry . Exclusion Criteria Coexisting Condition : Patients follow exclude : Corneal , lens , vitreous opacification precludes examination fundus . Clinically significant pulmonary neurologic impairment , include intubation coma . Karnofsky performance status = &lt; 50 . Concurrent Medication : Excluded : Immunomodulators . Biologic response modifier . Investigational agent ( erythropoietin investigational triazoles ) . Ganciclovir . Didanosine ( ddI ) . Systemic acyclovir . CMV hyperimmune serum / globulin . Interferons . Nephrotoxic agent include aminoglycosides , amphotericin B , parenteral pentamidine . Caution use concurrent use foscarnet ciprofloxacin , use appear exacerbate renal failure one patient . Patients follow exclude : Corneal , lens , vitreous opacification precludes examination fundus . Clinically significant pulmonary neurologic impairment , include intubation coma . Unwilling unable suspend zidovudine treatment 2nd week foscarnet maintenance therapy . Prior Medication : Excluded : Foscarnet cytomegalovirus retinitis . Systemic acyclovir . Immunomodulators . Biologic response modifier . Investigational agent ( erythropoietin investigational triazoles ) . AIDS patient active cytomegalovirus ( CMV ) retinitis treat ganciclovir . At least one pending CMV culture blood ( buffycoat ) urine must obtain prior study entry . Patients must able give informed consent . Patients history seizure disorder central nervous system mass lesion include .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>